



**From Passage Bio, a message to our community of patients, families, advocacy collaborators, health care providers, our employees and our larger network regarding the COVID-19 pandemic.**

April 27, 2020

At Passage Bio, the health and safety of patients, our employees, and their families remains our priority. We also feel a strong duty of responsibility to our broader communities to do our part to reduce the spread of COVID-19. The pandemic caused by the spread of COVID-19 is an unprecedented situation which we recognize places great strain upon the development of potentially transformative therapeutics that are especially needed by the rare disease communities we serve. We have therefore taken steps to protect our employees and contribute to the reducing of spread of COVID-19 in our communities while diligently working to advance the gene therapies we are developing.

We continue to focus on advancing our late-preclinical gene therapies for GM-1 gangliosidosis, FTD-PGN and Krabbe disease. We believe that these gene therapies will advance to clinical stage at the end of this year (GM-1) and first half of next year (FTD-PGN and Krabbe). As we continue to focus on the safety of patients and their families, we will work with the regulatory agencies and clinical trial sites to ensure any study initiations and patient enrollment can be accomplished with the highest standard of safety. We also recognize that clinicians, nurses and many people serving within our health care system are currently operating under great risk and strain. Our future clinical endeavors will also embark with a clear focus on the health and well-being of our medical care givers.

Passage Bio remains committed to using our resources to advance transformational therapeutics for patients with rare central nervous system diseases. Patients are at the center of every decision we make. We will continue aligning to the best possible approach for our families and patients, medical community, and external partners.